Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
Andrew Spencer, Simon J. Harrison, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Kenneth C. Anderson, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. , 128(22), DOI: https://doi.org/10.1182/blood.v128.22.3326.3326.
Article274 days agoPhase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
Andrew Spencer, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Simon J. Harrison, Amit Khot, Dharminder Chauhan, Kenneth C. Anderson, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2015). Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4220.4220.
Article274 days agoIsatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Shang‐Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson (2024). Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. , 109(7), DOI: https://doi.org/10.3324/haematol.2023.284325.
Article19 days agoReport of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Steven P. Treon, Alessandra Tedeschi, Jesús F. San Miguel, Ramón García‐Sánz, Kenneth C. Anderson, Eva Kimby, Monique C. Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S. Tam, Jorge J. Castillo, Pierre Morel, Meletios A Dimopoulos, Roger G. Owen (2023). Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. , 60(2), DOI: https://doi.org/10.1053/j.seminhematol.2023.03.009.
Article19 days agoReport of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Steven P. Treon, Alessandra Tedeschi, Jesús F. San Miguel, Ramón García‐Sánz, Kenneth C. Anderson, Eva Kimby, Monique C. Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S. Tam, Jorge J. Castillo, Pierre Morel, Meletios A Dimopoulos, Roger G. Owen (2023). Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. , 60(2), DOI: https://doi.org/10.1053/j.seminhematol.2023.03.009.
Article19 days ago